Biotech Values

[DewDiligence]

ABT—The Bloomberg piece you posted contains a plentiful measure of self-serving BS spouted by such analyst/bankers such as Jami Rubin of Goldman Sachs. (I commented on Rubin’s shameful performance on ABT’s CC yesterday in #msg-68128087.)

All this speculation about a buyout of ABT’s proprietary pharma successor company is premature insofar as ABT has not fully determined the allocation of assets and liabilities among the two successor companies. Moreover, it will be at least nine months until the split-off is implemented. By then, ABT’s inner circle might even come to their senses and realize that the main beneficiaries from all these machinations are not the shareholders, but rather the investment bankers.